UNSPSC 51386013: Pimetacin

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6RX3C7B5V. European Medicines Agency schedules Pimetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09839MIG. Pimetacin generally arises in the molecular formula C25H21CLN2O3S. The term PIMETACIN is an International Non-Proprietary Name or INN. PIMETACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule pimetacin under HS 29333999 and SITC 51574. As of Q4 2014, PIMETACIN remains the US FDA Preferred Term for this commodity. Pimetacin bears US NLM identifiers UMLS ID C1882380 and NCI Concept Code C66385. SMILES: CLC1CCC(C(=O)N2C(C(C3C2CCC(OC)C3)CC(=O)SCC2CCCNC2)C)CC1.

UNSPSC 51386013 Pimetacin is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products and related health-system consumables, though the recent solicitations show minimal direct alignment with pimetacin specifically and instead capture broader pharmaceutical procurement, naloxone distribution, and drug-supply-chain initiatives. State and local buyers soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, has pursued naloxone and drug deactivation systems through competitive sealed bidding; the Texas Health and Human Services Commission has used a Request for Information to assess vendor capacity for direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance has issued an RFP for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The work ranges from tactical procurement of specific emergency-response pharmaceuticals (naloxone) to strategic market research on alternative pharmaceutical-supply models and cooperative contracting frameworks that standardize pricing and wholesaler relationships across multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathered vendor input on direct-to-manufacturer prescription capabilities without a formal competitive timeline. The Minnesota MMCAP RFP S1070000015802, posted January 20, 2026, with a response deadline of March 26, 2026, established multiple-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and remaining points distributed across administrative compliance, EDI capability, and fee structure agreement. The code shows modest recent activity, and the opportunities posted do not emphasize pimetacin directly; the category may serve as a catch-all for pharmaceutical procurement that state and local buyers tag inconsistently with their actual needs.